

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
01 June 2023 (01.06.2023)



(10) International Publication Number
WO 2023/097329 A1

(51) International Patent Classification:

A61K 51/04 (2006.01) A61P 35/00 (2006.01)

C07B 59/00 (2006.01)

(21) International Application Number:

PCT/US2022/080572

(22) International Filing Date:

29 November 2022 (29.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/283,999 29 November 2021 (29.11.2021) US

(71) Applicant: **POINT BIOPHARMA, INC.** [US/US]; 4850 West 78th Street, Indianapolis, Indiana 46268 (US).

(72) Inventors: **FLESHNER, Neil**; 4850 West 78th Street, Indianapolis, Indiana 46268 (US). **JENSEN, Jessica**; 4850 West 78th Street, Indianapolis, Indiana 46268 (US). **MC-CANN, Joe**; 22 St. Clair Avenue East, Suite 1201, Toronto, Ontario M4T 2S3 (CA).

(74) Agent: **CORLESS, Peter F.** et al.; Fox Rothschild LLP, 997 Lenox Drive, Lawrenceville, New Jersey 08648 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: **RADIOPHARMACEUTICAL TREATMENT METHODS AND USE**

(57) Abstract: In one aspect, therapeutic use, methods of treatment and kits comprising ¹⁷⁷Lu-PSMA I&T are provided for subjects exhibiting prostate cancer progression following administration with one or more androgen receptor inhibitor agents.



WO 2023/097329 A1